Prestige Consumer Healthcare Cuts Revenue Outlook To $1,280 Million-$1,290 Million As Clear Eyes Supply Stays Tight
The company also lowered its adjusted EPS forecast to $4.48 to $4.55 on variable Clear Eyes output at its Pillar5 plant.
Prestige Consumer Healthcare, which sells branded consumer health products including Clear Eyes, cut its fiscal 2027 revenue forecast to $1,280 million to $1,290 million from $1,290 million to $1,315 million. CEO Ron Lombardi blamed recent variability in Clear Eyes production at the company's Pillar5 plant, which he said will reduce product availability and revenue in the second half.
Guidance comes down on every line
Adjusted diluted earnings per share are now forecast at $4.48 to $4.55, against $4.55 to $4.65 before. Organic revenue growth is now seen as about flat, versus the earlier 1% to 3%, and adjusted free cash flow at $265 million or more, from $270 million or more.
The company's slide deck says organic growth would be about 2% excluding Clear Eyes, and that it expects lower Clear Eyes sales in the second half than a year earlier. It also cites higher interest expense as a drag on EPS.
Lombardi said the outlook for the rest of the portfolio is unchanged. "While supply remains limited for Clear Eyes®, we continue to invest in our Pillar5 production site," he said.
A quarter of acquisitions and a Clear Eyes decline
Second-quarter revenue rose 22.7% to $336.3 million, helped by a $65.1 million contribution from the Breathe Right portfolio and LaCorium acquisitions. Excluding currency and acquisitions, revenue fell 1.6%, which the company tied to order timing in the first quarter and a decline in Clear Eyes.
Reported net income dropped to $25.3 million, or $0.53 a share, from $42.2 million, or $0.86. Adjusted EPS rose to $1.13 from $1.07. Net interest expense climbed to $30.0 million from $10.0 million.
Adjusted gross margin was 57.7%, up from 55.3%, while the standard-accounting gross margin fell to 51.3%. Adjusted figures exclude items such as inventory step-up amortization and Pillar5 remediation costs.
Debt now above $2 billion
Long-term debt stood at about $2.08 billion on September 30, up from $994 million at March 31, after the Breathe Right and LaCorium deals, which closed in June and July. Net debt was approximately $2 billion, and the company said paying it down is the priority for free cash flow for the rest of the fiscal year.
Prestige also issued $400 million of 6.25% senior notes due July 2034, replacing notes that had been due in fiscal 2028.
Lombardi reiterated a medium-term goal of about 10% annual revenue growth, and said the Pillar5 purchase gives the company vertical integration of its eye care supply chain.
Management hosted a call at 8:30 a.m. ET on Thursday to walk through the results and the revised outlook.
Sources
- 8-K Filing — Prestige Consumer Healthcare Inc. (PBH) — SEC EDGAR
- Exhibit exhibit991fy27-q2earningsr.htm — Prestige Consumer Healthcare Inc. 8-K exhibit — SEC EDGAR
- Exhibit exhibit992pbh_fy27xq2.htm — Prestige Consumer Healthcare Inc. 8-K exhibit — SEC EDGAR
- Prestige Consumer Healthcare: Fiscal Q2 Earnings Snapshot | 9news.com — Associated Press
- Prestige Consumer Healthcare Inc. Reports Fiscal 2027 — globenewswire.com